Riders · The University of Texas M.D. Anderson Cancer Center · Article III: Agencies of Education

Cell Therapy Institute

Rider 10 in the 2026-27 Act, page III-239

Through the session

  1. 2024-25 Act Not in this version
  2. Introduced (Senate) Not in this version
  3. Introduced (House) Not in this version
  4. Senate substitute Not in this version
  5. House substitute Not in this version
  6. House passed Not in this version
  7. Conference New rider 10
  8. 2026-27 Act Unchanged rider 10

Pick any two steps to compare their wording.

What changed in the text

Conference → 2026-27 Act: the same text in both versions.

Cell Therapy Institute. Out of funds appropriated above in Strategy D.1.3, Cell Therapy Institute, $15,000,000 from the General Revenue Fund in fiscal year 2026 and $15,000,000 from the General Revenue Fund in fiscal year 2027 shall be used for the Institute for Cell Therapy Discovery and Innovation. Any unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning September 1, 2026.

Removed words are struck through; added words are underlined. Sources: Conference · 2026-27 Act.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium Not in this version
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) Not in this version
Introduced (House)House Bill 1 as introduced (LBB recommended, House) Not in this version
Senate substituteCommittee Substitute for Senate Bill 1 Not in this version
House substituteHouse Committee Substitute for Senate Bill 1 Not in this version
House passedSenate Bill 1 as passed the second house Not in this version
ConferenceConference Committee Report for Senate Bill 1 10 New New Page III-215
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 10 Unchanged New Page III-239
Full text of each wording

Conference, 2026-27 Act

Source, page III-239

Cell Therapy Institute. Out of funds appropriated above in Strategy D.1.3, Cell Therapy Institute, $15,000,000 from the General Revenue Fund in fiscal year 2026 and $15,000,000 from the General Revenue Fund in fiscal year 2027 shall be used for the Institute for Cell Therapy Discovery and Innovation. Any unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning September 1, 2026.